The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a fusion protein TB vaccine candidate combined with the Toll-like Receptor 4 agonist adjuvant, GLA-SE. We conducted a ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Coler, Rhea N., Day, Tracey A., Ellis, Ruth, Piazza, Franco M., Beckmann, Anna Marie, Vergara, Julie, Rolf, Tom, Lu, Lenette, Alter, Galit, Hokey, David, Jayashankar, Lakshmi, Walker, Robert, Snowden, Margaret Ann, Evans, Tom, Ginsberg, Ann, Reed, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123489/
https://www.ncbi.nlm.nih.gov/pubmed/30210819
http://dx.doi.org/10.1038/s41541-018-0057-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123489/
https://www.ncbi.nlm.nih.gov/pubmed/30210819
http://dx.doi.org/10.1038/s41541-018-0057-5

Ejemplares similares